VIVERE ONCOTHERAPIES, INC.

Biotech · Private

Engineered oncolytic viruses designed to selectively replicate in tumors and deliver genetic cargo to overcome immunosuppression in colorectal cancer

Updated

Sector
Biotech
Total capital
$307K
Grants
$307K
1 award
At sector median 1 award
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median 2 patents

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history, newest first
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Translation of Evolved Oncolytic Virotherapy Product for Colorectal Cancer Treatment$306,871
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1088Chimera BioTechnology, Inc.——
1089Rattan Life Science Inc.——
1090KOI BIOTHERAPEUTICS INC.——
1091VIVERE ONCOTHERAPIES, INC.——
1092ByHeart, Inc.—$361M
1093BIOTECERA INC.——
1094Sidera Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

No people are linked to this company yet.

People appear here when they are named as related persons in the company's own Form D filings. We don't infer people from social profiles.

Checked: SEC EDGAR Form D related persons through

Patents

No patents are on record under this company's name.

USPTO publishes applications about 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won't match.

Checked: USPTO granted patents and published applications

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.